• Patients Ckd
    • Association Of Baclofen...
    • Association of Baclofen With Encephalopathy in Patients With Chronic Kidney Disease: Influence Statistics

      Expert Impact

      Concepts for whichthey havehas direct influence:Patients ckd,Baclofen encephalopathy,Baclofen users,Encephalopathy baclofen,Chronic kidney,Chronic kidney disease,Risk encephalopathy,Higher risk encephalopathy.

      Key People For Patients Ckd

      Top KOLs in the world
      Andrew S Levey
      kidney disease serum creatinine glomerular filtration rate
      Joseph Coresh
      atherosclerosis risk kidney disease african americans
      Tom H Greene
      kidney disease african americans blood pressure
      Glenn Matthew Chertow
      chronic kidney disease acute kidney injury united states
      John Walter Kusek
      chronic kidney disease urinary incontinence interstitial cystitis
      Adeera Levin
      kidney disease peritoneal dialysis british columbia

      Association of Baclofen With Encephalopathy in Patients With Chronic Kidney Disease


      Importance: At least 30 case reports have linked the muscle relaxant baclofen to encephalopathy in patients with chronic kidney disease (CKD).

      Objective: To compare the 30-day risk of encephalopathy in patients with CKD and newly prescribed baclofen at greater than or equal to 20 mg per day vs less than 20 mg per day. The secondary objective was to compare the risk of encephalopathy in baclofen users vs nonusers.

      Design, Setting, and Participants: Retrospective population-based cohort study in Ontario, Canada (2007-2018) using linked health care data. Participants comprised 15 942 older adults (aged 66 years or older) with CKD (defined as an estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m2 but not receiving dialysis). The primary cohort was restricted to patients who were newly prescribed baclofen; participants in the secondary cohort were new users and nonusers.

      Exposures: Prescription for oral baclofen greater than or equal to 20 mg per day vs less than 20 mg per day.

      Main Outcomes and Measures: Hospital admission with encephalopathy, defined as a main diagnosis of delirium, disorientation, transient alteration of awareness, transient cerebral ischemic attack, or unspecified dementia within 30 days of starting baclofen. Inverse probability of treatment weighting on the propensity score was used to balance comparison groups on indicators of baseline health. Weighted risk ratios (RRs) were obtained using modified Poisson regression and weighted risk differences (RDs) using binomial regression. Prespecified subgroup analyses were conducted by eGFR category.

      Results: The primary cohort comprised 15 942 patients with CKD (9699 [61%] women; median age, 77 years [interquartile range, 71-82]; 9707 [61%] patients started baclofen at ≥20 mg/d and 6235 [39%] at <20 mg/d). The primary outcome, hospitalization with encephalopathy, occurred in 108/9707 (1.11%) patients who started baclofen at greater than or equal to 20 mg per day and in 26/6235 (0.42%) who started baclofen at less than 20 mg per day; weighted RR, 3.54 (95% CI, 2.24 to 5.59); weighted RD, 0.80% (95% CI, 0.55% to 1.04%). In subgroup analysis, the absolute risk increased progressively at lower eGFR (weighted RD eGFR 45-59, 0.42% [95% CI, 0.19%-0.64%]; eGFR 30-44, 1.23% [95% CI, 0.62%-1.84%]; eGFR <30, 2.90% [95% CI, 1.30%-4.49%]; P for interaction, <.001]). In the secondary comparison with 284 263 nonusers, both groups of baclofen users had a higher risk of encephalopathy (<20 mg/d weighted RR, 5.90 [95% CI, 3.59 to 9.70] and ≥20 mg/d weighted RR, 19.8 [95% CI, 14.0 to 28.0]).

      Conclusions and Relevance: Among older patients with CKD who were newly prescribed baclofen, the 30-day incidence of encephalopathy was increased among those prescribed higher doses compared with lower doses. If verified, these risks should be balanced against the benefits of baclofen use.

      Sign-in to see all concepts, it's free!


    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.